4//SEC Filing
Chione Ltd 4
Accession 0001213900-19-003242
CIK 0001503802other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 8:12 PM ET
Size
52.8 KB
Accession
0001213900-19-003242
Insider Transaction Report
Form 4
Chione Ltd
10% Owner
Transactions
- Sale
COMMON STOCK
2019-02-26$5.00/sh−123,400$617,210→ 6,707,867 total - Sale
COMMON STOCK
2019-02-25$4.99/sh−800,000$3,994,880→ 6,831,267 total - Sale
COMMON STOCK
2019-02-27$4.51/sh−558,243$2,515,834→ 6,149,624 total
Czernik Marcin
10% Owner
Transactions
- Sale
COMMON STOCK
2019-02-25$4.99/sh−800,000$3,994,880→ 6,831,267 total - Sale
COMMON STOCK
2019-02-27$4.51/sh−558,243$2,515,834→ 6,149,624 total - Sale
COMMON STOCK
2019-02-26$5.00/sh−123,400$617,210→ 6,707,867 total
Hadjimichael Andreas
10% Owner
Transactions
- Sale
COMMON STOCK
2019-02-26$5.00/sh−123,400$617,210→ 6,707,867 total - Sale
COMMON STOCK
2019-02-25$4.99/sh−800,000$3,994,880→ 6,831,267 total - Sale
COMMON STOCK
2019-02-27$4.51/sh−558,243$2,515,834→ 6,149,624 total
Hadjimichael George
10% Owner
Transactions
- Sale
COMMON STOCK
2019-02-25$4.99/sh−800,000$3,994,880→ 6,831,267 total - Sale
COMMON STOCK
2019-02-27$4.51/sh−558,243$2,515,834→ 6,149,624 total - Sale
COMMON STOCK
2019-02-26$5.00/sh−123,400$617,210→ 6,707,867 total
Smolokowski Wiaczeslaw
10% Owner
Transactions
- Sale
COMMON STOCK
2019-02-27$4.51/sh−558,243$2,515,834→ 6,149,624 total - Sale
COMMON STOCK
2019-02-25$4.99/sh−800,000$3,994,880→ 6,831,267 total - Sale
COMMON STOCK
2019-02-26$5.00/sh−123,400$617,210→ 6,707,867 total
Footnotes (5)
- [F1]The prices reported in Column 4 are weighted average prices. The shares were sold on 02/25/2019 at prices ranging from $4.80 to $5.31, inclusive, on 02/26/2019 at prices ranging from $5.00 to $5.08, inclusive, and on 02/27/2019 at prices ranging from $4.40 to $4.675, inclusive.
- [F2]The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above.
- [F3]Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.
- [F4]Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed.
- [F5]Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
IncorporatedCyprus
Related Parties
1- filerCIK 0001590232
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 8:12 PM ET
- Size
- 52.8 KB